Merit Medical Systems vs Penumbra
MMSI and PEN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MMSI and PEN compare
Penumbra is the larger company, worth 2.4 times as much as Merit Medical Systems ($12.6B against $5.1B).
On earnings, Merit Medical Systems is cheaper: it trades at 32.4× trailing earnings, against 80.3× for Penumbra.
Penumbra grew revenue faster over the last twelve months (17.0% versus 9.1% for Merit Medical Systems).
Penumbra keeps more of each dollar of sales as profit, with a net margin of 10.1% compared with 9.9% at Merit Medical Systems.
Penumbra scores higher on the StockData Score (15 against 13 for Merit Medical Systems), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MMSI | PEN |
|---|---|---|
| Size and price | ||
| Market cap | $5.1B | $12.6B |
| Share price | $86.24 | $318.95 |
| Change, 1 year | 6.0% | 36.7% |
| Change, 5 years | 24.2% | 11.8% |
| Beta (5Y) | 0.68 | 0.87 |
| Employees | 7,500 | 4,700 |
| StockData Score | ||
| Total score | 13 | 15 (better) |
| Valuation score | 4 (better) | 2 |
| Growth score | 2 | 3 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 32.4× (better) | 80.3× |
| P/S | 3.2× (better) | 8.1× |
| P/B | 3.0× (better) | 7.9× |
| EV/EBITDA | 15.7× (better) | 56.8× |
| P/FCF | 25.3× (better) | 62.7× |
| PEG | 1.78 | – |
| FCF yield | 4.0% (better) | 1.6% |
| Fair value | $92.68 | $184.29 |
| Margin of safety | 6.9% (better) | −73.1% |
| Growth | ||
| Revenue growth (TTM) | 9.1% | 17.0% (better) |
| Revenue growth, 5Y average | 9.5% | 20.2% (better) |
| Net income growth (TTM) | 35.2% (better) | −4.3% |
| EPS growth (TTM) | 36.4% (better) | −4.1% |
| Profitability | ||
| Gross margin | 49.4% | 68.0% (better) |
| Operating margin | 13.5% (better) | 12.1% |
| Net margin | 9.9% | 10.1% (better) |
| FCF margin | 12.6% | 12.8% (better) |
| Return on equity | 9.8% | 10.7% (better) |
| Return on invested capital | 8.5% | 15.9% (better) |
| Financial health | ||
| Debt / equity | 0.42 (better) | 0.00 |
| Net debt / EBITDA | 0.68 | – |
| Interest coverage | 6.7× | 149× (better) |
| Current ratio | 4.52 | 5.89 (better) |
| Altman Z-score | 4.25 | 19.07 (better) |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.43% | – |
| Shareholder yield | −0.43% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 105% | 86.7% |
| Held by insiders | 2.7% | 3.4% |
| Insider net buying, 12 months | −$7.9M (better) | −$11.1M |
| Short interest, % of float | 6.2% | 5.9% |
Go deeper
- MMSI stock overview
- MMSI income statement
- MMSI valuation and score
- PEN stock overview
- PEN income statement
- PEN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.